Sponsors (2)
The bill would create standardized, community-informed, and regularly updated PFAS clinical and public-health guidance—improving care and coordination—while imposing federal contracting costs, administrative burdens on clinicians, and some timeline risk if contracts are delayed.
PFAS-exposed patients (including people with chronic conditions and parents/families) and their clinicians will have standardized, evidence-based clinical guidance—regularly updated (every 5 years or sooner)—for diagnosing and managing PFAS-related health effects, improving care consistency and ensuring recommendations reflect current science.
State and local public health authorities will receive authoritative guidance to coordinate testing, follow-up, and community response to PFAS exposure, strengthening local public-health planning and reducing fragmented responses.
PFAS-exposed communities (rural and urban families) will be consulted during guidance development, increasing relevance, community trust, and the likelihood guidance addresses local needs.
Taxpayers may incur additional federal costs to contract with the National Academies and to support ongoing updates and dissemination of the guidance.
Clinicians, hospitals, and health systems may face repeated administrative burden and short-term costs to adapt practice protocols to new guidance updates.
If the contracted entity delays or declines the work, the statutory 60-day and 2-year deadlines may be impractical, risking missed timelines for guidance availability and slowing local responses.
Based on analysis of 2 sections of legislative text.
Requires ATSDR to contract for an independent assessment of PFAS measurable in human tissues and to produce and periodically update clinical guidance for health authorities and clinicians.
Introduced January 8, 2026 by Maxine Dexter · Last progress January 8, 2026
Directs the Agency for Toxic Substances and Disease Registry (ATSDR) to contract with the National Academies (or a similar entity) to assess health effects of PFAS that can be measured in human tissues and to develop clinical recommendations. The contract must be entered within 60 days of enactment; the assessing body must deliver an initial assessment and clinical recommendations within 2 years and update them at least every 5 years. ATSDR must use those products to issue, post, and disseminate up-to-date clinical guidance to state/local public health authorities and appropriate clinicians within 5 years after the agreement and then every 5 years or sooner if needed. The assessing body must engage PFAS-exposed communities during the process.